
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. With a substantial majority of its revenue generated from life sciences customers, OPRX's financial success is closely tied to the overall market conditions and policy changes that may impact the biopharma industry. Despite potential risks, OPRX maintains its 2026 revenue/EBITDA outlook and expects to see a return to growth in 2027, reaffirming its market outperform rating. The company's differentiating factors, including its ability to deliver personalized electronic messages to healthcare providers and its diverse revenue streams, position OPRX for long-term success.
Bears say
OptimizeRx is facing significant challenges in the healthcare market, and its FY26 revenue guidance has been reduced due to a macro slowdown, lowered revenue from a top client, and general headwinds. While the company's connection with demand-side platforms (DSPs) has potential to drive future revenue, the timing and impact of this integration remains unclear. Additionally, persistent contraction in contracted revenues and uncertainties surrounding customer spending patterns further add to the negative outlook for the company.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares